SCHEMBL7186699

SCHEMBL7186699

CCCOc1ccc(PC(=O)c2c(C)cccc2C)c(C)c1.[LiH]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
LMNA P02545 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
ATM Q13315 1/20 0.39
SLC5A1 P13866 1/20 0.38
SLC5A2 P31639 1/20 0.38
ACACB O00763 1/20 0.38
FFAR1 O14842 3/20 0.37
PPARD Q03181 1/20 0.37
SLC13A5 Q86YT5 1/20 0.37
SMARCA2 P51531 1/20 0.37
SMARCA4 P51532 1/20 0.37
BRD9 Q9H8M2 1/20 0.37
CYP1A2 P05177 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NR1H4 Q96RI1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188475 0.95 THRB (0.41) KMT2APPARDNR1H4
SCHEMBL7177011 0.93 THRA (0.45) TP53
SCHEMBL7183768 0.92 KMT2A (0.40) KMT2AMAPTTP53LMNAL3MBTL1
SCHEMBL7186708 0.91 THRA (0.46) TP53
SCHEMBL7174697 0.90 KMT2A (0.43) KMT2AMAPTTP53LMNAL3MBTL1
SCHEMBL7179721 0.90 KMT2A (0.43) KMT2AMAPTTP53LMNAL3MBTL1
SCHEMBL7189018 0.90 ITGB1 (0.42) KMT2AMAPTLMNAL3MBTL1SLC5A1
SCHEMBL7177209 0.90 SMN1; SMN2 (0.41) KMT2AMAPTTP53LMNAL3MBTL1
SCHEMBL7180671 0.89 FFAR1 (0.43) KMT2AMAPTLMNAL3MBTL1FFAR1
SCHEMBL7188420 0.89 TDP1 (0.39) LMNAL3MBTL1ATMFFAR1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1200943-C Organometallic acyl-aryl phosphine CIBA SC HOLDING AG (CH) 2005-05-11 CN disclosed
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed
CN-1308081-A Organometallic acyl-aryl phosphine CIBA SC HOLDING AG (CH) 2001-08-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MAPT 4870/4885TP53 3575/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MAPT 4859/4885TP53 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.